Summary: Stars and Stripes reports on the $50,000 grant gifted to MAPS from the Navy SEAL Foundation in support of completing MAPS-sponsored Phase 3 trials of MDMA-assisted psychotherapy for PTSD, the final stage in the FDA approval process to make MDMA a legal treatment option for PTSD. The grant is the largest in the foundation’s history, confirming a need for more treatment options for PTSD and highlighting the potential of a novel solution. “This pioneering work has shown great promise,” says Robin King, Navy SEAL Foundation CEO, regarding clinical results from completed Phase 2 trials of MDMA-assisted psychotherapy for PTSD. “We’re leaning in to help [Naval Special Warfare] and other veterans overcome the debilitating effects of PTSD,” explains King.
Originally appearing here.